SOLO 1: Olaparib in BRCA mutated patients
Maintenance olaparib provides a clinically meaningful improvement in OS for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. The 7-year follow-up data support its use for long-term remission.